Phase I study of recombinant CEA vaccinia virus vaccine with post vaccination CEA peptide challenge.
Cole
D J
DJ
MUSC Dept. of Surgery, Charleston, South Carolina, 29425, USA.
Wilson
M C
MC
Baron
P L
PL
O'Brien
P
P
Reed
C
C
Tsang
K Y
KY
Schlom
J
J
D000230:Adenocarcinoma / Q000517:prevention & control*; D000328:Adult; D000368:Aged; D000818:Animals; D001943:Breast Neoplasms / Q000517:prevention & control*; D002272:Carcinoembryonic Antigen / Q000235:genetics / Q000276:immunology*; D002985:Clinical Protocols; D004305:Dose-Response Relationship, Drug; D004361:Drug Tolerance; D005260:Female; D005770:Gastrointestinal Neoplasms / Q000517:prevention & control*; D005822:Genetic Vectors; D006801:Humans; D008175:Lung Neoplasms / Q000517:prevention & control*; D008297:Male; D008875:Middle Aged; D010455:Peptides; D014611:Vaccination; D014614:Vaccines, Synthetic; D014616:Vaccinia virus / Q000235:genetics*; D014765:Viral Vaccines
D002272:Carcinoembryonic Antigen; D010455:Peptides; D014614:Vaccines, Synthetic; D014765:Viral Vaccines